Shreehas Tambe, CEO & managing director of Biocon Biologics, discusses the way that US tariff & manufacturing policy affects ...

India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease ...

Biocon Biologics Managing Director and CEO Shreehas Tambe says the board has not recommended any action on a potential IPO or ...

Biocon shares hit a new 52-week high after the company confirmed it is evaluating a potential merger of Biocon Biologics with ...

India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease ...

Several brokerages raised target price for the stock, suggesting strong upside potential from the market price.

MOFSL and JM Financial retained their Buy ratings, while Nuvama upgraded Biocon to Buy from Hold after the company posted a ...

CEO Siddharth Mittal believes Biocon’s existing portfolio, including liraglutide, gives it an edge in a highly competitive ...

Global biosimilar development typically costs between $100 million and $200 million, but the U.S. Food and Drug Administration’s updated recommendations aim to eliminate expensive comparative efficacy ...

SBI Mutual Fund has raised its stake in Biocon to over 5% after purchasing 3,70,150 shares. “SBI Mutual Fund under its ...

Solid earnings, robust biosimilars growth, and improving margins drive renewed optimism; analysts see double-digit upside potential in the stock.

The biosimilars segment, which contributes 61% of Biocon’s total sales, recorded revenue of ₹2,720 crore in the second ...